Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001104659-11-009371
Filing Date
2011-02-23
Accepted
2011-02-23 17:08:11
Documents
9
Period of Report
2010-12-31

Document Format Files

Seq Description Document Type Size
1 10-K a11-1850_110k.htm 10-K 4412948
2 EX-10.32 a11-1850_1ex10d32.htm EX-10.32 64843
3 EX-21 a11-1850_1ex21.htm EX-21 6447
4 EX-23.1 a11-1850_1ex23d1.htm EX-23.1 2349
5 EX-31.1 a11-1850_1ex31d1.htm EX-31.1 12019
6 EX-31.2 a11-1850_1ex31d2.htm EX-31.2 12165
7 EX-32.1 a11-1850_1ex32d1.htm EX-32.1 5741
8 EX-32.2 a11-1850_1ex32d2.htm EX-32.2 5826
9 GRAPHIC g18501ba13i001.gif GRAPHIC 13590
  Complete submission text file 0001104659-11-009371.txt   4542965
Mailing Address P.O. BOX 110526 RESEARCH TRIANGLE PARK NC 27709
Business Address 4101 RESEARCH COMMONS 79 T.W. ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709 919-316-6300
Talecris Biotherapeutics Holdings Corp. (Filer) CIK: 0001405197 (see all company filings)

EIN.: 202533768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-34473 | Film No.: 11633000
SIC: 2834 Pharmaceutical Preparations